Patents Assigned to Suzhou Alphamab Co., Ltd.
-
Patent number: 11912768Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.Type: GrantFiled: July 7, 2021Date of Patent: February 27, 2024Assignees: SUZHOU ALPHAMAB CO., LTD., XITIAN ZHANG, XIN ZHANGInventors: Ting Xu, Xiaoxiao Wang, Jie Li, Haiyan Wu, Li Gao, Qian Chu, Yu Bai
-
Publication number: 20230061378Abstract: The invention relates to the field of biomedicine, and an anti-pertussis toxin (PT) single domain antibody and derivative protein thereof are disclosed. Specifically, a pertussis toxin-binding protein and use thereof are disclosed.Type: ApplicationFiled: July 1, 2020Publication date: March 2, 2023Applicant: Suzhou Alphamab Co., Ltd.Inventors: Ting Xu, Xiaoxiao Wang, Ling Wang, Danming Zhu, Li Gao
-
Publication number: 20220325000Abstract: Disclosed is a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof.Type: ApplicationFiled: August 28, 2020Publication date: October 13, 2022Applicant: Suzhou Alphamab Co., Ltd.Inventors: Ting Xu, Xiaoxiao Wang, Ying Fan, Yanrong Dong, Liping Chen, Jianyun Ji
-
Patent number: 11377497Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.Type: GrantFiled: January 23, 2018Date of Patent: July 5, 2022Assignee: SUZHOU ALPHAMAB CO., LTD.Inventors: Ting Xu, Aiwu Zhou, Yuhao Jin, Ling Wang, Jie Wu, Hongqin Hu, Xiaoxiao Wang
-
Publication number: 20220017643Abstract: The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.Type: ApplicationFiled: October 7, 2021Publication date: January 20, 2022Applicants: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., SUZHOU ALPHAMAB CO., LTD.Inventor: Ting XU
-
Patent number: 11225522Abstract: The present invention relates to the field of medical biology and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecule and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.Type: GrantFiled: August 1, 2016Date of Patent: January 18, 2022Assignee: Suzhou Alphamab Co., LTD.Inventors: Ting Xu, Yanrong Dong, Pilin Wang, Ting Chen
-
Patent number: 11168149Abstract: The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.Type: GrantFiled: December 16, 2016Date of Patent: November 9, 2021Assignees: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., SUZHOU ALPHAMAB CO., LTD.Inventor: Ting Xu
-
Patent number: 11091549Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.Type: GrantFiled: May 19, 2017Date of Patent: August 17, 2021Assignees: SUZHOU ALPHAMAB CO., LTD., XITIAN ZHANG, XIN ZHANGInventors: Ting Xu, Xiaoxiao Wang, Jie Li, Haiyan Wu, Li Gao, Qian Chu, Yu Bai
-
Publication number: 20190352404Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KNO35 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.Type: ApplicationFiled: January 23, 2018Publication date: November 21, 2019Applicant: SUZHOU ALPHAMAB CO., LTD.Inventors: Ting XU, Aiwu ZHOU, Yuhao JIN, Ling WANG, Jie WU, Hongqin HU, Xiaoxiao WANG
-
Publication number: 20180362668Abstract: A heterodimer molecule based on CH3, and a preparation method therefor and a use thereof. By comprehensively considering various interactions between molecules, for example, an ionic action, a hydrophobic interaction and a spatial action, a preferred Fc mutant sequence being more inclined to form a heterodimer rather than a homodimer is screened, and accordingly, the yield of the heterodimer molecule is greatly improved, thereby creating conditions for the preparation of bispecific molecules and the like.Type: ApplicationFiled: December 16, 2016Publication date: December 20, 2018Applicants: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., SUZHOU ALPHAMAB CO., LTD.Inventor: Ting XU
-
Patent number: 9969786Abstract: Disclosed herein is a gonadotropin fusion protein or a thyroid stimulating hormone fusion protein, a method for preparing the same and use thereof. ?-subunit of the gonadotropin or thyroid stimulating hormone is fused to an Fc fragment directly or indirectly through a linker, and ?-subunit binds to the ?-subunit via an affinity between the ?-subunit and the ?-subunit. The fusion protein has a prolonged half-life and less fluctuating activity.Type: GrantFiled: November 22, 2013Date of Patent: May 15, 2018Assignee: Suzhou Alphamab Co, Ltd.Inventors: Ting Xu, Kangping Guo, Lihong Yun
-
Patent number: 9708389Abstract: The invention relates to a method for preparing a homodimer protein mixture by using repulsive interaction of charges. The method comprises the step of replacing part of residues with the opposite-charged residues, so that different proteins or antibodies are unfavorable to forming heterodimers due to the repulsive interaction between like charges, while same proteins or antibodies are favorable to forming homodimers due to attractive interaction between opposite charges. The homodimer protein mixture obtained according to the method of the invention can simultaneously act on different epitopes of the same target, and simultaneously inhibit the effects of a plurality of antigens by binding to the antigens from different sources, thereby providing a new approach towards immunological diagnosis and treatment of tumors and other diseases.Type: GrantFiled: July 25, 2013Date of Patent: July 18, 2017Assignee: Suzhou Alphamab Co., Ltd.Inventors: Ting Xu, Tao Xu, Xiaoxiao Wang, Xinglu Sun, Ying Fan, Yan Zeng